ClinicalTrials.gg
CompletedNCT06420765Updated Apr 20, 2025

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

A Phase 1 interventional study of VX-150 and VX-548 in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-20.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.

Enrollment
4th of 21
92 · median 50
Started
2024
with 1 other
Phase 1
15 of 21
none open now
Registered
10th of 21
by date
Lead sponsor
15 of 21
Vertex Pharmaceuticals Incorporated

Among the 21 studies testing suzetrigine in Pain, this one is the 4th largest by enrollment, is one of 2 that started in 2024, is one of 15 in phase 1, and was the 10th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing suzetrigine in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effects of Nav1.8 inhibition on activity-dependent slowing (ADS) of C-nociceptor nerve fibers, evoked action potential (AP) conduction velocity of C-nociceptor nerve fibers using VX-150, VX-993 and VX-548.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m\^2)
  • A total body weight of more than (>) 50 kg

Key Exclusion Criteria:

  • History of febrile illness or other acute illness that has not fully resolved within 14 days before study drug dosing
  • Any condition possibly affecting drug absorption
  • Any dermatological (generalized) or disease that may affect C-nociceptor excitability
  • Participants with Type 1 or Type 2 diabetes mellitus
  • Participants who have any 1 of the following criteria in the foot in which microneurography (MNG) will be performed:

    • Injection of local anesthetics or within 35 days prior to randomization.
    • Unsuitable anatomy of the superficial peroneal nerve (i.e., nerve cannot be seen or palpated at the dorsum of the foot)
    • Infection, disease (dermatologic or vascular), ongoing pain, or recent trauma or surgery that may affect study assessments Note: Participants must have 1 foot that does not meet any of the above criteria to be eligible.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    VX-150

    Participants will be randomized to receive a single dose of VX-150.

    Drug: VX-150

  • Experimental
    VX-548

    Participants will be randomized to receive a single dose of different dose levels of VX-548

    Drug: VX-548

  • Experimental
    VX-993

    Participants will be randomized to receive a single dose of different dose levels of VX-993.

    Drug: VX-993

  • Placebo comparator
    Placebo

    Participants will receive single dose of non-matching placebo.

    Drug: Placebo

Interventions

  • DrugVX-150

    Suspension for oral administration.

  • DrugVX-548

    Solution or suspension for oral administration.

  • DrugVX-993

    Suspension for oral administration.

  • DrugPlacebo

    Suspension for oral administration.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Activity Dependent Slowing (ADS) Over Time

    Time frame: From Pre-dose up to 2-hours Post Dose

Secondary outcomes

  1. Change From Baseline in Conduction Velocity at 0.25 Hz Over Time

    Time frame: From Pre-dose up to 2-hours Post Dose

  2. Change From Baseline in Action Potential (AP) Latency at 0.25 Hz Over Time

    Time frame: From Pre-dose up to 2-hours Post Dose

  3. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE)

    Time frame: From Day 1 up to Day 16

07

Study locations

1 site
  • MAC Clinical Research
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Mar 2025, 10 months.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 10 months is above that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
May 20, 2024
StartActual
May 21, 2024
Primary completionActual
Mar 22, 2025
CompletionActual
Apr 4, 2025
Last update
Apr 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06420765
Responsible party
Sponsor
First posted
May 20, 2024
Start date
May 21, 2024
Primary completion
Mar 22, 2025
Completion
Apr 4, 2025
Last update
Apr 20, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: VX-150 · Suzetrigine · VX-993

Start the discussion